Study Finds Key Differences in Lungs of Cystic Fibrosis Patients Skip to main content Close Select your preferred language English عربى 简体中文 繁體中文 فارسي עִברִית 日本語 한국어 Русский Español Tagalog Menu Close Call 1-800-CEDARS-1 toggle search form Close Los Angeles, 06 May 2021 08:40 AM America/Los_Angeles Study Finds Key Differences in Lungs of Cystic Fibrosis Patients Healthy airways (left) show well-defined layers of ciliated cells (green) and basal stem cells (red). In airways affected by cystic fibrosis (right), the layers are disrupted, and scientists identified a transitioning cell type that combines properties of both stem cells and ciliated cells (red and green in the same cell). Image courtesy of Nature Medicine. Researchers Catalog of Airway Cell Types Could Reveal Targets for Future Genetic Therapies A team of researchers from UCLA, Cedars-Sinai and the Cystic Fibrosis Foundation has developed a first-of-its-kind molecular catalog of cells in healthy lungs and the lungs of people with cystic fibrosis. The catalog, described today in the journal Nature Medicine, reveals new subtypes of cells and illustrates how the disease changes the cellular makeup of the airways. The findings could help scientists in their search for specific cell types that represent prime targets for genetic and cell therapies for cystic fibrosis. A progressive genetic disorder that affects more than 70,000 people worldwide, cystic fibrosis results from mutations to the CFTR gene. Cells that contain the defective protein encoded by the gene produce unusually thick and sticky mucus that builds up in the lungs and other organs. This mucus clogs the airways, trapping germs and bacteria that can cause life-threatening infections and irreversible lung damage. While several new therapies can partially restore the function of these damaged proteins, easing symptoms of the disease, slowing its progression and improving quality of life, these treatments only work in people with some of the many CFTR mutations that can cause cystic fibrosis. The research team was assembled through the Cystic Fibrosis Foundation's Epithelial Stem Cell Consortium, which brings together scientists from across the U.S. in an ongoing effort to identify different subtypes of stem cells in the lungs and study their function. Because these cells can self-renew and produce a continuous supply of specialized cells that maintain, repair and regenerate the airways, therapies aimed at correcting CFTR mutations in stem cells hold the best hope for a one-time, universal treatment for the disease. "We were surprised to find that the airways of people with cystic fibrosis showed differences in the types and proportions of basal cells, a cell category that includes stem cells responsible for repairing and regenerating upper airway tissue, compared with airways of people without this disease," said Barry Stripp, PhD, professor of Medicine and director of the Lung Stem Cell Program at the Cedars-Sinai Board of Governors Regenerative Medicine Institute. Specifically, the researchers discovered that among the basal cell populations, there was a relative overabundance of cells that appear to be transitioning from basal stem cells into specialized ciliated cells, which use their finger-like projections to clear mucus out of the lungs. "We suspect that changes the basal cells undergo to replenish ciliated cells represent an unsuccessful attempt to clear mucus that typically accumulates in airways of patients with cystic fibrosis," Stripp said. The increase in transitioning cells provides further evidence suggesting that expression of the mutated CFTR gene disrupts normal function of the airways, leading to changes in the way that basal stem cells produce specialized cells. For the study, Stripp and his senior co-authors, Brigitte Gomperts, MD, and Kathrin Plath, PhD, both of UCLA, and John (Jed) Mahoney, PhD, of the Cystic Fibrosis Foundation, compared tissue samples taken from lungs removed from 19 people with cystic fibrosis, all of whom had received lung transplants, with samples taken from healthy lungs donated by 19 individuals who had died from other causes. Researchers at the three institutions employed similar but distinct methods to break these tissues down and examine them using a technology called single-cell RNA sequencing, which allowed them to analyze thousands of cells in tandem and classify them into subtypes based on their gene expression patterns-this is, which genes are turned on and off. "The process is analogous to taking a smoothie and 'un-blending' it to discover all the ingredients it contains and measure how much of each ingredient was used," said Plath, a professor of Biological Chemistry and a member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. Using a novel computer-based bioinformatics approach to compare the gene expressions patterns of the various cells, the team was able to create a catalog of the cell types and subtypes present in healthy airways and those affected by cystic fibrosis, including some previously unknown subtypes that illuminate how the disease alters the cellular landscape of the airways. "This new research has provided us with valuable insights into the cellular makeup of both healthy and diseased airways," said Gomperts, a member of the UCLA Broad Stem Cell Research Center and professor of Pediatrics and Pulmonary Medicine at the David Geffen School of Medicine at UCLA. "If you can understand how things work in a state of health, it becomes easier to see what cellular and molecular changes occur in a disease state." She added: "This catalog represents an important step toward identifying those rare stem cells that regenerate the airways over a person's lifetime. We suspect these cells could be targets for future therapies that may provide a long-term correction to the mutation that causes this disease." Moving forward, the researchers will continue to study the new data for insights into how cystic fibrosis alters the cellular landscape of the airways-including why this unsuccessful transition occurs-and to identify the long-lived basal stem cells that would be the ideal target for a CFTR gene correction. "We have made tremendous progress in the development of treatments for the underlying cause of cystic fibrosis, but many people cannot benefit from these medicines," said Mahoney, head of the stem cell biology team at the Cystic Fibrosis Foundation Therapeutics Lab. "This research provides critical insight into how the disease alters the cellular makeup of the airways, which will enable scientists to better target the next generation of transformative therapies for all people with cystic fibrosis." The co-first authors of the study were Gianni Carraro, PhD, from Cedars-Sinai and Justin Langerman, PhD, from UCLA. Funding: This research was supported by the Cystic Fibrosis Foundation, the Tobacco-Related Disease Research Program, the National Heart, Lung, and Blood Institute, the National Institutes of Health, the National Cancer Institute, the W.M. Keck Foundation, Celgene, the Howard Hughes Medical Institute, a Parker B. Francis Foundation Fellowship, a UCLA Broad Stem Cell Research Center Rose Hills Foundation Graduate Scholarship, and the UCLA Tumor Cell Biology Training Program. DOI:10.1038/s41591-021-01332-7 Read more about lung stem cells in Discoveries: Breathing Room Related Stories RSS feed - Related Stories (opens in new window) View all headlines - Related Stories Fine-Tuning Organ-Chip Technology Scientists Develop a New Method to Better Visualize and Analyze Multicellular Interactions October 07, 2022 07:03 AM America/Los_Angeles A new method developed by scientists at Cedars-Sinai makes it easier to visualize the cell populations in organ chips, the technology that recapitulates true-to-life biology outside the body.Induced pluripotent stem cell and organ-chip technologies … Read more Share this release (opens in dialog) 15 Years of Heart Cedars-Sinai Marks A Decade-and-a-Half Since Founding the Smidt Heart Institute Leading to Breakthroughs in Cardiac Care Surgery and Disease Prevention October 03, 2022 06:01 AM America/Los_Angeles Pioneering heart care is a tradition at Cedars-Sinai. It’s a tradition that took root in 1924, when Cedars-Sinai became home to the first electrocardiogram machine in Los Angeles. The roots grew stronger in the 1970s, when two Cedars-Sinai … Read more Share this release (opens in dialog) Gut Gases Linked to Specific Types of Irritable Bowel Syndrome Cedars-Sinai Investigators Find Breath Testing IBS Patients May Lead to More Effective Treatment September 30, 2022 06:09 AM America/Los_Angeles A new study led by Cedars-Sinai investigators found using breath tests to identify gut gas profiles can potentially help lead to more personalized therapies for people diagnosed with irritable bowel syndrome (IBS). The most common gastrointestinal … Read more Share this release (opens in dialog) Show previous items Show next items Contact the Media Team Email: [email protected] Contact Share this release Study Finds Key Differences in Lungs of Cystic Fibrosis Patients Share on: Twitter Share on: Facebook Share on: LinkedIn Search Our Newsroom Social media Visit our Facebook page (opens in new window) Follow us on Twitter (opens in new window) Visit our Youtube profile (opens in new window) (opens in new window) Latest news 07 Oct 2022 - HealthDay: Black Women Less Likely to Get Laparoscopic Fibroid Surgeries 07 Oct 2022 - Faculty Publications: Sept. 29-Oct. 6 07 Oct 2022 - Fine-Tuning Organ-Chip Technology 06 Oct 2022 - KCRW: Want New Omicron Booster? Wait at Least 2 Months After Last Shot 05 Oct 2022 - Cedars-Sinai Schedules Free Flu Vaccine Clinics 04 Oct 2022 - Cedars-Sinai Showcases Hispanic and Latinx Art Newsroom Home